Search review questions

Comfort (long‐term effect) Measured at more than 24 hours, scales were standardized to allow comparison; higher numbers indicate more comfort · adults in the ICU, requiring respiratory support

Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support

In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support

Mortality at longest · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a…

Number of days ventilated · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a…

Requirement for inotropic support (scale from 0 to 28, days of catecholamine use) · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a…

Requirement for renal replacement therapy ( · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a…

Quality of life · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a…

28‐Day all‐cause mortalitya · children and adults with sepsis

Long‐term mortalityc · children and adults with sepsis

Hospital mortality · children and adults with sepsis

Length of intensive care unit stay for all participants in days · children and adults with sepsis

Length of hospital stay for all participants in days · children and adults with sepsis

Number of participants with adverse events ‐ superinfection (up to longest · children and adults with sepsis

Number of participants with adverse events ‐ muscle weakness (up to longest · children and adults with sepsis

Early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28; day 60; and in hospital · adults with acute respiratory distress syndrome

Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome

Adverse events Defined as leading to discontinuation of study medication; data collected during study period · adults with acute respiratory distress syndrome

Fitness to return to work at 12 months · adults with acute respiratory distress syndrome

Early all‐cause mortality (≤ 3 months) Reported at: 30 days · adults with acute respiratory distress syndrome

Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome

Duration of mechanical ventilation · adults with acute respiratory distress syndrome

Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome

Adverse events Defined as leading to discontinuation of study medication · adults with acute respiratory distress syndrome

Fitness to return to work at 12 months · adults with acute respiratory distress syndrome

Early all‐cause mortality (≤ 3 months) Reported at: 60 days; and during hospital stay · adults with acute respiratory distress syndrome

Late all‐cause mortality ( > 3 months) Reported at: 180 days · adults with acute respiratory distress syndrome

Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome

Duration of mechanical ventilation Measured in days · adults with acute respiratory distress syndrome

Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome

Adverse events Defined as leading to discontinuation of study medication · adults with acute respiratory distress syndrome

Fitness to return to work at 12 months · adults with acute respiratory distress syndrome

Early all‐cause mortality (≤ 3 months) Reported at: 28 days; 60 days; and during hospital stay · adults with acute respiratory distress syndrome

Late all‐cause mortality (> 3 months · adults with acute respiratory distress syndrome

Duration of mechanical ventilation · adults with acute respiratory distress syndrome

Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome

Adverse events Defined as leading to discontinuation of study medication; data collected during study period · adults with acute respiratory distress syndrome

Duration of mechanical ventilation Measured in days · adults with acute respiratory distress syndrome

Fitness to return to work at 12 months · adults with acute respiratory distress syndrome

Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome

Adverse events Defined as leading to discontinuation of study medication; or for studies with standard care control, defined by study authors as "serious adverse events" · adults with acute respiratory distress syndrome

Fitness to return to work at 12 months · adults with acute respiratory distress syndrome

Early all‐cause mortality (≤ 3 months) Reported at: 28 days; and 90 days. Time point not reported in 4 studies · adults with acute respiratory distress syndrome

Late all‐cause mortality ( > 3 months) Reported at: 180 days · adults with acute respiratory distress syndrome

Duration of mechanical ventilation Measured in days · adults with acute respiratory distress syndrome

Typical antipsychotic vs placebo · critically ill adults with confirmed or at high risk of delirium

Typical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

Atypical antipsychotics vs placebo · critically ill adult with confirmed or at high risk of delirium

Statin (HMG‐CoA)vs placebo · critically ill adult with confirmed or at high risk of delirium

Alpha2 agonist vs placebo · critically ill adult with confirmed or at high risk of delirium